

## **Organic Acids Profile**

Provider: sample Patient: sample Accession #: 2000123456 Sex: Age: Sample Type: Urine Card Collected: 2023-04-11 Received: 2023-04-11 Completed:

Analyte (/	Result ug/mg creatinine)	Reference Range	Population Percentile	
Glycolysis				
1. Pyruvate	1.08	< 1.90	66% -	1.08
2. Lactate	17.41	< 23.35	83% -	17.41
Citric Acid Cycle				
3. Citrate	581.24	71.30 - 772.63	86%	581.24
4. Cis-Aconitate (H)	53.01	< 40.54	91%	-(53.01)
5. Isocitrate (H)	102.83	19.94 - 74.88	97%	102.83
6. Alpha-Ketoglutarate (H)	36.08	< 18.94	93% –	- 36.08
7. Succinate (H)	62.58	< 20.99	99%	62.58
8. Fumarate (H)	>ULOQ	< 1.13	N/A	N/A
9. Malate (H)	20.72	< 2.62	97%	20.72
Fatty Acid Oxidation	$\langle$		$\langle \bigcirc \rangle$	
10. Adipate (H)	14.65	< 4.42	96% -	-14.65
11. Suberate (H)	2.71	< 2.64	90% -	2.71
12. Ethylmalonate	3.15	< 3.88	83% -	3.15
13. Methylsuccinate	1.82	< 2.20	82% -	1.82
Markers for Protein Metabolism	102	$\overline{}$		
14. Alpha-Ketoisovalerate	0.35	< 0.49	76% –	0.35
15. Alpha-Ketoisocaproate	0.99	< 1.09	88% -	0.99
16. Alpha-Keto-Beta-Methylvalerate (H)	2.91	< 1.29	92% -	(2.91
17. Beta-Hydroxyisovalerate (H)	9.85	< 8.86	90% -	9.85
18. Methylmalonate	0.70	< 1.64	24% -	0.70
19. Hydroxymethylglutarate	4.04	< 7.20	38% -	4.04

Reference range updated 5/21/2021. Reference range is not gender adjusted. Reference range is age adjusted for children. Method: LC/MS/MS. LLOQ: Lower limit of quantitation ULOQ: Upper limit of quantitation. Lactate is reported as D- and L-Lactate combined on OAP. This test is not intended to diagnose, treat, cure, or prevent any disease or replace the medical advice and/or treatment obtained from a qualified healthcare practitioner. US BioTek Laboratories has developed and determined the performance characteristic of this test under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been evaluated by the U.S. Food and Drug Administration. This test does not assess for neonatal inborn errors of metabolism and is based on stable renal function and normal renal clearance.



## **Organic Acids Profile**

Provider: sample Patient: sample Accession #: 2000123456 Sex: Age: Sample Type: Urine Card **Collected:** 2023-04-11 **Received:** 2023-04-11 **Completed:** 

Analyte	<b>Result</b> (µg/mg creatinine)	Reference Range	Population Percentile
Ketone Metabolites			
20. Alpha-Hydroxybutyrate (H)	4.52	< 1.24	91% - 4.52
21. Beta-Hydroxybutyrate (H)	>ULOQ	< 8.09	N/A – N/A
Markers of Neurotransmitter Metal	bolism		
22. Vanilmandelate (H)	4.16	< 3.64	90% - 4.16
23. Homovanillate	3.19	< 6.66	48%
24. 5-Hydroxyindoleacetate	2.27	1.17 - 8.06	37% - 2.27
25. Quinolinate	2.74	< 5.37	34% - 2.74
26. Kynurenate	1.25	< 2.49	33%
Markers of Detoxification			
27. Para-Hydroxyphenyllactate (H)	1.80	< 1.55	90% - 1.80
28. Orotate	0.42	< 1.04	24% - 0.42
29. Pyroglutamate	34.05	14.58 - 37.47	91% - 34.05-
30. Benzoate	<lloq< td=""><td>&lt; 6.87</td><td>N/A N/A</td></lloq<>	< 6.87	N/A N/A
31. Hippurate	28.66	17.13 - 768.53	10% - 28.66
Markers of Bacterial Metabolism	$\langle \gamma \rangle \langle \langle \rangle$	$\sim$	
32. Para-Hydroxybenzoate	0.53	< 1.43	60% - 0.53
33. Para-Hydroxyphenylacetate	15.96	< 26.39	69% –
34. 2-Hydroxyphenylacetate (H)	1.95	< 1.24	93% – 1.95
35. 3-Indoleacetate	1.71	0.46 - 9.21	45% -
36. Tricarballylate	<lloq< td=""><td>&lt; 1.06</td><td>N/A N/A</td></lloq<>	< 1.06	N/A N/A

Reference range updated 5/21/2021. Reference range is not gender adjusted. Reference range is age adjusted for children. Method: LC/MS/MS. LLOQ: Lower limit of quantitation ULOQ: Upper limit of quantitation. Lactate is reported as D- and L-Lactate combined on OAP. This test is not intended to diagnose, treat, cure, or prevent any disease or replace the medical advice and/or treatment obtained from a qualified healthcare practitioner. US BioTek Laboratories has developed and determined the performance characteristic of this test under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been evaluated by the U.S. Food and Drug Administration. This test does not assess for neonatal inborn errors of metabolism and is based on stable renal function and normal renal clearance.



## **Environmental Pollutants Profile**

Provider: sample Patient: sample Accession #: 2000123456 Sex: Age: Sample Type: Urine Card Collected: 2023-04-11 Received: 2023-04-11 Completed:

Analyte	<b>Result</b> (µg/mg creatinine)	Reference Range	Population Percentile				
Xylene Exposure							
1. 3-Methylhippurate	0.03	< 0.18	20% - 0.03				
2. 2-Methylhippurate	<lloq< td=""><td>&lt; 0.06</td><td>N/A N/A</td></lloq<>	< 0.06	N/A N/A				
Toluene Exposure							
3. Hippurate	28.66	< 768.53	10% - 28.66				
4. Benzoate	<lloq< td=""><td>&lt; 6.87</td><td>N/A NA</td></lloq<>	< 6.87	N/A NA				
Benzoate is metabolized to Hippurate. Elevations may cause elevated Hippurate independent of Toluene.							
Benzene Exposure							
5. t,t-Muconic Acid	<lloq< td=""><td>&lt; 0.15</td><td></td></lloq<>	< 0.15					
Trimethylbenzene Exposure							
6. 3,4-Dimethylhippurate	<lloq< td=""><td>&lt; 0.01</td><td>N/A (N/A)-</td></lloq<>	< 0.01	N/A (N/A)-				
Styrene Exposure							
7. Mandelate	0.28	< 0.34	80% - 0.28				
8. Phenylglyoxylate	0.14	< 0.30	37% - 0.14				
9. Mandelate + Phenylglyoxylate	0.42	< 0.61	64% - 0.42 -				
Phthalate Exposure	$\langle \gamma \rangle \leq \langle$						
10. Monoethyl Phthalate	0.06	< 0.10					
11. Phthalate	0.05	< 0.17	29% - 0.05				
12. Quinolinate	2.74	< 5.37	34% - 2.74 -				
Paraben Exposure							
13. Para-Hydroxybenzoate	0.53	< 1.43	60% - 0.53				
Methyl Tert-butyl Ether Exposure							
14. Alpha-Hydroxyisobutyrate (H)	8.39	< 6.35	91% - 8.				

Reference range updated 5/21/2021. Reference range is not gender adjusted. Reference range is age adjusted for children. Method: LC/MS/MS. LLOQ: Lower limit of quantitation ULOQ: Upper limit of quantitation. Lactate is reported as D- and L-Lactate combined on OAP. This test is not intended to diagnose, treat, cure, or prevent any disease or replace the medical advice and/or treatment obtained from a qualified healthcare practitioner. US BioTek Laboratories has developed and determined the performance characteristic of this test under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been evaluated by the U.S. Food and Drug Administration. This test does not assess for neonatal inborn errors of metabolism and is based on stable renal function and normal renal clearance.